Severe Treatment-Related Adverse Events

Risks & contraindications

Highlighted claims

• Severe treatment-related adverse events favoured dual targeted therapy because ICI caused more grade 3 or higher toxicity. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
• The pooled risk ratio indicated about an 18% higher relative risk of grade 3 or higher toxicity with ICI. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
• Grade 3 or higher toxicity exceeded 50% in the ICI combination arm according to editorial commentary cited by the article. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials